Keen Kevzara Pricing Will Be Sanofi’s Best Hope After Speedy NICE Nod
A three-month turnaround from approval in Europe for Sanofi’s rheumatoid arthritis drug to recommendation in England is pretty quick. The firm will need to maintain keen pricing in a competitive field.
You may also be interested in...
Global R&D President Elias Zerhouni said Sanofi has the knowledge and skills it needs to discover antibody drugs internally and it's time to end the perception that Regeneron is keeping Sanofi's R&D humming.
After returning to the neuroscience space in the summer through a big-money deal with Alector, GlaxoSmithKline is setting up an institute with the University of Oxford that will target neurological diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis, frontal temporal dementia, ALS and pain.
Private Company Edition: Scrip spoke with DDF US partner Jonathan Behr about the convergence of emerging science, venture capital investment and rising big pharma interest in neurodegeneration. Also, in recent VC financings HotSpot raised $100m, while Curie and Ablaze debuted with $75m each.